Equities Analysts Offer Predictions for CORT Q1 Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Equities researchers at Zacks Research upped their Q1 2026 earnings estimates for Corcept Therapeutics in a note issued to investors on Monday, January 27th. Zacks Research analyst K. Das now anticipates that the biotechnology company will post earnings of $0.46 per share for the quarter, up from their previous forecast of $0.45. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.35 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q2 2026 earnings at $0.56 EPS, Q3 2026 earnings at $0.74 EPS, Q4 2026 earnings at $0.74 EPS and FY2026 earnings at $2.50 EPS.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.27 by $0.14. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The firm had revenue of $182.55 million during the quarter, compared to the consensus estimate of $171.97 million. During the same period last year, the firm earned $0.28 EPS. The business’s quarterly revenue was up 47.7% compared to the same quarter last year.

Several other research analysts have also commented on CORT. Sandler O’Neill restated a “buy” rating on shares of Corcept Therapeutics in a report on Friday, October 18th. HC Wainwright reissued a “buy” rating and set a $80.00 price objective on shares of Corcept Therapeutics in a research report on Thursday, October 31st. Finally, StockNews.com downgraded shares of Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 25th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $65.25.

Corcept Therapeutics Trading Up 1.4 %

Shares of CORT opened at $61.53 on Wednesday. Corcept Therapeutics has a 1-year low of $20.84 and a 1-year high of $62.98. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.70 and a quick ratio of 3.64. The company has a market capitalization of $6.45 billion, a P/E ratio of 48.83 and a beta of 0.56. The firm’s 50 day simple moving average is $55.55 and its 200 day simple moving average is $46.50.

Insider Buying and Selling at Corcept Therapeutics

In other Corcept Therapeutics news, insider William Guyer sold 6,606 shares of the stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $48.97, for a total transaction of $323,495.82. Following the completion of the sale, the insider now directly owns 5,796 shares of the company’s stock, valued at approximately $283,830.12. This represents a 53.27 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Joseph Douglas Lyon sold 1,411 shares of the company’s stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $56.72, for a total value of $80,031.92. Following the transaction, the insider now directly owns 8,494 shares in the company, valued at $481,779.68. This represents a 14.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 38,011 shares of company stock worth $1,951,268 over the last quarter. Insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Corcept Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Capital Performance Advisors LLP purchased a new position in shares of Corcept Therapeutics during the 3rd quarter worth $25,000. Kathleen S. Wright Associates Inc. acquired a new stake in shares of Corcept Therapeutics in the third quarter valued at $36,000. USA Financial Formulas purchased a new stake in shares of Corcept Therapeutics during the fourth quarter worth approximately $54,000. Newbridge Financial Services Group Inc. acquired a new stake in Corcept Therapeutics in the fourth quarter valued at $58,000. Finally, GAMMA Investing LLC grew its position in shares of Corcept Therapeutics by 85.4% in the 3rd quarter. GAMMA Investing LLC now owns 2,490 shares of the biotechnology company’s stock valued at $115,000 after buying an additional 1,147 shares during the last quarter. 93.61% of the stock is currently owned by institutional investors and hedge funds.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.